CMS

The Medicare Administrative Contractor's decision covers molecular diagnostic laboratory tests as predictive classifiers for non-small cell lung cancer.

The new rate applies to clinical diagnostic lab tests using high-throughput technologies that can process more than 200 specimens per day.

Under the guidance, group health plans and group and individual health insurers must cover diagnostic testing and other "certain related items and services."

The agency will reimburse at about $35.91 per test for CDC assays and about $51.31 per test for non-CDC assays.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

Medicare Administrative Contractor Palmetto released its final local coverage decision last year, and WPSIC has now aligned its coverage.

The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.